Tempus products

Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, colorectal, endometrial, prostate, pancreatic) and others (renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, select pediatric tumors, select hematologic malignancies). xG (common hereditary cancers): Covers genes associated with six of the most common hereditary cancer types (Breast, Ovarian,Colorectal, Endometrial, Prostate, Pancreatic)

Tempus xE (version 2) is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. Clinical sequencing is performed to 500x depth of coverage for tumor specimens and 150x for normal specimens for the clinically enhanced regions (648 genes). Non-enhanced regions are performed at 250x depth of coverage for tumor specimens and 150x for normal specimens.

648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor Origin (TO), Homologous Recombination Deficiency (HRD), DPYD